New hope for advanced breast cancer: safety trial launches in india

NCT ID NCT06429761

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tests the safety of trastuzumab deruxtecan, a targeted drug that delivers chemotherapy directly to HER2-positive cancer cells. It involves 100 Indian adults with advanced or spreading breast cancer who have already tried another HER2-targeted treatment. The main goal is to monitor side effects and ensure the drug is safe for this population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Bangalore, 560017, India
Research Site
RECRUITING

Delhi, 110029, India
Research Site
RECRUITING

Kochi, 682041, India
Research Site
RECRUITING

Mumbai, 400012, India
Research Site
RECRUITING

Pune, 411028, India
Research Site
RECRUITING

Varanasi, 221005, India

Conditions

Explore the condition pages connected to this study.

BREAST CANCER